Our high-quality biopharmaceuticals expand treatment opportunities
Remsima is medicine for autoimmune diseases. As the world’s first antibody biosimilar trusted by pharmaceutical regulators and patients across the world, Remsima offers efficacy and safety that have been evidenced by the cumulative number of prescriptions and long-term clinical study results. Celltrion Pharm has been supplying Remsima for a reasonable price in the Korean market, thereby achieving a socioeconomic innovation that allows more patients to enjoy the benefits of the drug.
Celltrion Pharm has improved patient convenience and expanded treatment options for physicians by supplying Remsima SC in the domestic market. Remsima SC, the world’s first subcutaneous formulation of infliximab, enhances the administration convenience of Remsima IV (intravenous formulation). This groundbreaking biopharmaceutical is reshaping the global blockbuster drug market.
Celltrion Pharm offers Truxima, a blood cancer medicine, and Herzuma, a breast cancer medicine, in the Korean market, thereby providing cancer patients with access to high-quality biopharmaceutical products at reasonable prices. With these high-quality products, the company proved its competitive edge by expanding its market share in the Korean anticancer biosimilar sector.
Celltrion Pharm is venturing beyond the mere supply of biopharmaceuticals to embrace new business opportunities. As part of its efforts to expand its product pipeline, the company has established aseptic facilities and a prefilled syringe (PFS) production line. Through global certification processes, Celltrion Pharm is producing subcutaneous biopharmaceuticals such as Remsima SC.